Skip to content
Open access

PCSK9 Inhibitors and Risk of Aortic Stenosis in Atherosclerotic Cardiovascular Disease

Sep 2026 · JACC: Advances · Vol 5 · 0 citations · 39 references
Medicine

TL;DR

In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS, and this findings are hypothesis-generating.

Abstract

Background Atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis (AS) share lipid-related mechanisms. Although statins have not slowed established AS progression in randomized trials, whether proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are associated with lower incident AS risk remains uncertain. Objectives The objective of the study was to assess the association between PCSK9is use and incident AS in statin-treated patients with ASCVD. Methods Using TriNetX, we conducted a retrospective new-user cohort study of adults aged ≥60 years with ASCVD receiving statins from January 1, 2015, to August 31, 2025. PCSK9is were compared with statin-only users after 1:1 propensity score matching. The primary outcome was new-onset AS within 5 years; secondary outcomes included all-cause mortality, heart failure exacerbation (HFE), and aortic valve replacement. Results After 1:1 matching, 22,924 patients remained in each group. PCSK9is use was associated with a lower risk of AS (HR: 0.87; 95% CI: 0.78-0.97; P = 0.012), all-cause mortality, and HFE. Aortic valve replacement reduction was not significant. Subgroup analyses showed statistically significant interaction was observed only for chronic kidney disease and heart failure. Conclusions In statin-treated patients with ASCVD, PCSK9i use was associated with a modestly lower 5-year incidence of new-onset AS. Large mortality and HFE associations may reflect residual confounding and treatment-selection bias. These findings are hypothesis-generating.

Read PDF

Similar papers

Sep 2026

Association Between PCSK9 Inhibitor Use and Risk of Incident Heart Failure in Patients With Dyslipidemia.

AIM To evaluate whether the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) is associated with a reduced 1-year incidence of new-onset heart failure (HF) compared to statins among patients with dyslipidemia. METHODS We conducted a retrospective cohort study using the TriNetX global health re...

Jheng-Yan Wu, Keng-Wei Lee, Sheng-Chi Huang et al. · 0 citations
Open access Sep 2026

Add-On PCSK9 Inhibitor Therapy for Acute Stroke Attributable to Intracranial Atherosclerosis: A Randomized Clinical Trial.

BACKGROUND Intracranial atherosclerotic stenosis is a major cause of ischemic stroke with high recurrence rates despite intensive therapy. The efficacy of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) as adjunctive treatment in intracranial atherosclerotic stenosis remains unclear. METHODS We cond...

Yi-Ting Pan, Yuan-Hsiung Tsai, Hsu-Huei Weng et al. · 0 citations
Open access Sep 2026

Remnant cholesterol predicts adverse clinical outcomes in patients with hypertension: a post hoc analysis of the ALLHAT

In both the White population and hypertensive individuals with age below 65 years, statin treatment has demonstrated significant reductions in the incidence of ASCVD events, and Cumulative and time-weighted average RC showed positive but imprecise associations with ASCVD.

Teng Ma, Xiao-Lu Hu, Bo-Hao Xue et al. · 0 citations
Case report Open access Oct 2026

SGLT2 inhibitors and cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy: A propensity score-matched cohort study.

SGLT2 inhibitor use was associated with favorable cardiovascular outcomes in patients with moderate-to-severe psoriasis receiving biologic therapy, and these findings support further prospective investigation of SGLT2 inhibitors as a potential strategy for cardiovascular risk reduction in this population.

A. Gotor-Rivera, J. Hernández-Sánchez, E. Chamorro-Jiménez et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.